Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCH | P24723 | 7/20 | 0.55 |
| ▸ | PRKCE | Q02156 | 7/20 | 0.55 |
| ▸ | PRKCQ | Q04759 | 7/20 | 0.55 |
| ▸ | PRKCD | Q05655 | 7/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | AURKA | O14965 | 2/20 | 0.47 |
| ▸ | TTK | P33981 | 2/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.47 |
| ▸ | INCENP | Q9NQS7 | 2/20 | 0.47 |
| ▸ | PRKCZ | Q05513 | 2/20 | 0.47 |
| ▸ | LATS1 | O95835 | 1/20 | 0.47 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.47 |
| ▸ | CLK1 | P49759 | 1/20 | 0.46 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.46 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29650673 | 0.78 | PRKCD (0.51) | PRKCHPRKCEPRKCQPRKCDLMNA | |
| SCHEMBL3324615 | 0.78 | PRKCD (0.51) | PRKCHPRKCEPRKCQPRKCDLMNA | |
| SCHEMBL5659114 | 0.77 | LMNA (0.55) | LMNACYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5656944 | 0.76 | IMPDH2 (0.55) | LMNACYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL23301031 | 0.73 | LMNA (0.46) | PRKCHPRKCEPRKCQPRKCDLMNA | |
| SCHEMBL31375795 | 0.73 | PRKCD (0.56) | PRKCHPRKCEPRKCQPRKCDCYP1A2 | |
| SCHEMBL11374306 | 0.73 | PRKCD (0.56) | PRKCHPRKCEPRKCQPRKCDCYP1A2 | |
| SCHEMBL3326285 | 0.73 | PRKCH (0.47) | PRKCHPRKCEPRKCQPRKCDCYP1A2 | |
| SCHEMBL5656993 | 0.71 | CYP1A2 (0.49) | LMNACYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL30218963 | 0.71 | CYP1A2 (0.49) | LMNACYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3615537-A2 | 6-6 FUSED BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS LATS INHIBITORS | Novartis AG (CH) | 2020-03-04 | — | — | EP | disclosed |
| WO-2018198077-A2 | 6-6 FUSED BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS LATS INHIBITORS | NOVARTIS AG (CH) | 2018-11-01 | — | — | WO | disclosed |
| US-20100130469-A1 | 2, 6-NAPHTHRIDINE DERIVATIVES | VAN EIS MAURICE | 2010-05-27 | — | — | US | disclosed |
| EP-2144908-A1 | 2, 6-NAPHTHYRIDINE DERIVATIVES AS PROTEIN KINASE MODULATORS | Novartis Ag (CH) | 2010-01-20 | — | — | EP | disclosed |
| WO-2008122614-A1 | 2, 6-NAPHTHYRIDINE DERIVATIVES AS PROTEIN KINASE MODULATORS | NOVARTIS AG (CH) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130469-A1 | 2, 6-NAPHTHRIDINE DERIVATIVES | PKN1, PKN2, CDK9 | PRKCH 22/4885PRKCE 18/4885PRKCQ 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.